Equities

Genus PLC

GNS:LSE

Genus PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3,035.00
  • Today's Change5.00 / 0.17%
  • Shares traded66.48k
  • 1 Year change67.31%
  • Beta1.3960
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Genus PLC grew net income 144.30% 7.90m to 19.30m despite relatively flat revenue growth.
Gross margin--
Net profit margin2.87%
Operating margin6.30%
Return on assets2.05%
Return on equity3.88%
Return on investment2.40%
More ▼

Cash flow in GBPView more

In 2025, Genus PLC increased its cash reserves by 12.94%, or 5.50m. The company earned 67.20m from its operations for a Cash Flow Margin of 9.99%. In addition the company used 13.80m on investing activities and also paid 46.60m in financing cash flows.
Cash flow per share0.9695
Price/Cash flow per share31.16
Book value per share7.21
Tangible book value per share4.82
More ▼

Balance sheet in GBPView more

Genus PLC has a Debt to Total Capital ratio of 35.84%, a lower figure than the previous year's 52.59%.
Current ratio1.94
Quick ratio1.32
Total debt/total equity0.5585
Total debt/total capital0.3584
More ▼

Growth rates in GBP

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 141.87%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)1.20%
Div growth rate (5 year)1.92%
Payout ratio (TTM)35.23%
EPS growth(5 years)-11.75
EPS (TTM) vs
TTM 1 year ago		142.28
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.